What are the North American Intergroup Study C9710 induction therapy regimen for the treatment of acute promyelocytic leukemia (APL)?

Updated: Jul 02, 2019
  • Author: Sandy D Kotiah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


North American Intergroup Study C9710 regimen  [3]  :

  • ATRA 45 mg/m 2/day PO in 2 divided doses starting on day 1 and continuing until complete remission or a maximum of 90 days  plus
  • Daunorubicin 50 mg/m 2 IVP on days 3-6  plus
  • Cytarabine 200 mg/m 2/day continuous IV infusion over 24 h on days 3-9

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!